Returns
| Series | 1 week | 1 month | 3 months | 6 months | YTD | 1 year | 3 years (ann.) | 5 years (ann.) | 10 years (ann.) | Since inception (ann.) |
|---|---|---|---|---|---|---|---|---|---|---|
| Market-price return | -2.13% | -12.33% | -9.34% | -4.86% | -6.57% | -7.94% | +0.71% | -6.29% | -1.91% | -4.46% |
| Market-price total return | -2.13% | -11.58% | -6.97% | +0.37% | +1.37% | +2.67% | +12.91% | +4.29% | +8.79% | +5.73% |
| NAV return | -1.59% | -8.55% | -9.95% | -2.36% | -4.54% | -6.20% | +1.67% | -4.08% | — | -1.77% |
| NAV total return | -1.59% | -7.75% | -7.63% | +2.93% | +3.45% | +4.38% | +14.05% | +7.18% | — | +8.94% |
Performance through Oct 14, 2026. Price and NAV returns are simple changes; total returns reinvest each distribution at the series value on its ex-date (first observation on/after). Periods of one year or less are cumulative; longer periods are annualised. Series are built from unadjusted prices plus the distribution record so no distribution is counted twice. Corporate actions: the vendor price series is split-adjusted; rights offerings and mergers are not restated — check Corporate Actions.
Growth of $10,000, five years
Risk statistics
| Statistic | Market price | NAV | Specification |
|---|---|---|---|
| Volatility, 1 year | 0.20% | 0.22% | annualised SD of daily total returns, √252 |
| Volatility, 3 years | 0.19% | 0.19% | as above |
| Volatility, 5 years | 0.19% | 0.18% | as above |
| Maximum drawdown, 3 years | -20.05% | -18.88% | peak-to-trough on the total-return index |
| Sharpe ratio, 3 years | 0.49 | 0.59 | excess over FRED DGS3MO (window average) (avg 4.52%), annualised |
| Sortino ratio, 3 years | 0.68 | 0.90 | downside deviation of excess returns |
| Beta vs. benchmark proxy, 3 years | 0.55 | — | SPY (U.S. equity ETF proxy), daily, aligned dates |
| Correlation, 3 years | 0.44 | — | as above |
| Observations (3y) | 751 | — | minimum 60; rankings require 500 |
Market-price and NAV volatility are different quantities and are never mixed. NAV volatility for funds holding stale-marked or illiquid assets can understate economic risk.
CEF Explorer research page for abrdn World Healthcare Fund. Figures carry their own dates and sources; a discount to NAV does not guarantee convergence or any return. This is not investment advice.